Icon Plc $ICLR Shares Acquired by Heartland Advisors Inc.

Heartland Advisors Inc. lifted its position in Icon Plc (NASDAQ:ICLR) by 99.4% in the 1st quarter, HoldingsChannel reports. The firm owned 16,066 shares of the medical research company’s stock after purchasing an additional 8,008 shares during the quarter. Heartland Advisors Inc.’s holdings in Icon were worth $1,778,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Toth Financial Advisory Corp purchased a new stake in Icon in the fourth quarter valued at approximately $27,000. EFG International AG purchased a new position in Icon during the 4th quarter worth approximately $27,000. Abound Financial LLC purchased a new position in Icon during the 4th quarter worth approximately $54,000. Johnson Financial Group Inc. acquired a new stake in Icon during the 3rd quarter valued at approximately $71,000. Finally, Blue Trust Inc. lifted its stake in Icon by 207.5% during the 1st quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock valued at $73,000 after acquiring an additional 444 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

ICLR has been the topic of a number of research reports. Jefferies Financial Group reiterated a “buy” rating and issued a $165.00 price objective on shares of Icon in a research note on Friday, May 29th. Barclays boosted their target price on shares of Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research report on Thursday, June 25th. BMO Capital Markets upped their price target on shares of Icon from $160.00 to $187.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Piper Sandler lowered shares of Icon to a “neutral” rating in a report on Thursday, May 28th. Finally, DA Davidson set a $164.00 price target on Icon in a research report on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $173.19.

Icon Price Performance

Shares of NASDAQ ICLR opened at $170.00 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 1.14. The stock has a market capitalization of $13.02 billion, a price-to-earnings ratio of 30.25, a PEG ratio of 8.34 and a beta of 1.22. The firm’s 50 day simple moving average is $146.22 and its 200-day simple moving average is $136.69. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.